Biblio
Export 185 results:
Author Title Type Year Filters: Keyword is Amyloid beta-Peptides [Clear All Filters]
“The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 49, no. 2, pp. 547-60, 2016.
, “The Oral Iron Chelator, Deferasirox, Reverses the Age-Dependent Alterations in Iron and Amyloid-β Homeostasis in Rat Brain: Implications in the Therapy of Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 3, pp. 681-93, 2016.
, “Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.”, Lancet Neurol, vol. 12, no. 2, pp. 207-16, 2013.
, “APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.”, Ann Neurol, vol. 67, no. 1, pp. 122-31, 2010.
, “Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration.”, Proc Natl Acad Sci U S A, vol. 108, no. 14, pp. 5819-24, 2011.
, “Memory impairment in transgenic Alzheimer mice requires cellular prion protein.”, J Neurosci, vol. 30, no. 18, pp. 6367-74, 2010.
, “Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders.”, Ann Neurol, vol. 70, no. 4, pp. 532-40, 2011.
, “Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.”, Neuron, vol. 69, no. 2, pp. 203-13, 2011.
, “Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease.”, Nature, vol. 467, no. 7311, pp. 95-8, 2010.
, “Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness.”, Cell Stem Cell, vol. 12, no. 4, pp. 487-96, 2013.
, “Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta.”, Neuron, vol. 78, no. 4, pp. 631-43, 2013.
, “Subjective Memory Complaints in APOEɛ4 Carriers are Associated with High Amyloid-β Burden.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1115-22, 2016.
, “The Anti-Amyloid-β Monoclonal Antibody 4G8 Recognizes a Generic Sequence-Independent Epitope Associated with α-Synuclein and Islet Amyloid Polypeptide Amyloid Fibrils.”, J Alzheimers Dis, vol. 50, no. 2, pp. 517-25, 2016.
, “Multifunctional Effect of Human Serum Albumin Reduces Alzheimer's Disease Related Pathologies in the 3xTg Mouse Model.”, J Alzheimers Dis, vol. 50, no. 1, pp. 175-88, 2016.
, “A three-dimensional human neural cell culture model of Alzheimer's disease.”, Nature, vol. 515, no. 7526, pp. 274-8, 2014.
, “REST and stress resistance in ageing and Alzheimer's disease.”, Nature, vol. 507, no. 7493, pp. 448-54, 2014.
, “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
, “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
, “A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β.”, Sci Transl Med, vol. 4, no. 147, p. 147ra111, 2012.
, “An epigenetic blockade of cognitive functions in the neurodegenerating brain.”, Nature, vol. 483, no. 7388, pp. 222-6, 2012.
, “Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition.”, Arch Neurol, vol. 69, no. 5, pp. 636-43, 2012.
, “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
, “Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.”, J Neuropathol Exp Neurol, vol. 70, no. 11, pp. 960-9, 2011.
, “Evidence for ordering of Alzheimer disease biomarkers.”, Arch Neurol, vol. 68, no. 12, pp. 1526-35, 2011.
, “Human apoE isoforms differentially regulate brain amyloid-β peptide clearance.”, Sci Transl Med, vol. 3, no. 89, p. 89ra57, 2011.
,